

UPDATED FDA Warning Regarding Semaglutide | Tirzepatide September, 2023



Following more than a dozen reports of intestinal blockages among people using the diabetes drug Semaglutide, the FDA announced that the potentially life-threatening condition will be listed on the drug's label.

The medical term for intestinal blockage is "Ileus," and 18 cases of it in people taking Semaglutide have been reported to the FDA.

The FDA has received more than 8,500 reports of gastrointestinal issues among people taking medications like Ozempic and Wegovy - [generic name Semaglutide] the latter of which is approved for weight loss. Ileus is mentioned in 33 cases, including two deaths, of people taking drugs containing Semaglutide, which is the active ingredient in Ozempic, Wegovy, and another widely used weight loss drug called Mounjaro.

The FDA stopped short of saying there is a direct link between [Semaglutide and Tirzepatide] and intestinal blockages.

"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure," the FDA said in its approval of the label update.

If you are electively taking Semaglutide or Tirzepatide for weight loss, there is a known risk for:

- | | |
|---|--------------------------------|
| 1. Ileus Gastroparesis Stomach Paralysis | 5. Hypoglycemia |
| 2. Nausea Vomiting Diarrhea Abdominal Pain and Cramping | 6. Acute Kidney Injury |
| 3. Pancreatitis | 7. Hypersensitivity Reactions: |
| 4. Diabetic Retinopathy Complications | 8. Acute Gallbladder Disease |

Do NOT take Semaglutide or Tirzepatide if:

- | | |
|---|---|
| 1. You are pregnant, breast feeding or attempting to become pregnant. | 3. History of pancreatitis |
| 2. Have a history of Multiple Endocrine Neoplasia Type II | 4. History suicidal thoughts or severe depression |

OMary, Lisa. WebMD. 28 Sept 2023. <https://www.webmd.com/obesity/news/20230928/risk-of-intestinal-blockage-added-to-ozempic-label>

UPDATED FDA Warning Regarding Semaglutide | Tirzepatide September, 2023



Following more than a dozen reports of intestinal blockages among people using the diabetes drug Semaglutide, the FDA announced that the potentially life-threatening condition will be listed on the drug's label.

The medical term for intestinal blockage is "Ileus," and 18 cases of it in people taking Semaglutide have been reported to the FDA.

The FDA has received more than 8,500 reports of gastrointestinal issues among people taking medications like Ozempic and Wegovy - [generic name Semaglutide] the latter of which is approved for weight loss. Ileus is mentioned in 33 cases, including two deaths, of people taking drugs containing Semaglutide, which is the active ingredient in Ozempic, Wegovy, and another widely used weight loss drug called Mounjaro.

The FDA stopped short of saying there is a direct link between [Semaglutide and Tirzepatide] and intestinal blockages.

"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure," the FDA said in its approval of the label update.

If you are electively taking Semaglutide or Tirzepatide for weight loss, there is a known risk for:

- | | |
|---|--------------------------------|
| 1. Ileus Gastroparesis Stomach Paralysis | 5. Hypoglycemia |
| 2. Nausea Vomiting Diarrhea Abdominal Pain and Cramping | 6. Acute Kidney Injury |
| 3. Pancreatitis | 7. Hypersensitivity Reactions: |
| 4. Diabetic Retinopathy Complications | 8. Acute Gallbladder Disease |

Do NOT take Semaglutide or Tirzepatide if:

- | | |
|---|---|
| 1. You are pregnant, breast feeding or attempting to become pregnant. | 3. History of pancreatitis |
| 2. Have a history of Multiple Endocrine Neoplasia Type II | 4. History suicidal thoughts or severe depression |

OMary, Lisa. WebMD. 28 Sept 2023. <https://www.webmd.com/obesity/news/20230928/risk-of-intestinal-blockage-added-to-ozempic-label>